| Cash Flow | 2025-09-30 |
|---|---|
| Net income | 123 |
| Amortization of right-of-use assets | 250 |
| Depreciation and amortization | 77 |
| Stock based compensation | 49 |
| Change in deferred tax assets | 68 |
| Other, net | 3 |
| Accounts receivable, net | -1,447 |
| Inventories | 1,107 |
| Other current assets | 87 |
| Accounts payable | 533 |
| Accrued expenses and other liabilities | 188 |
| Operating lease obligations | -243 |
| Net cash provided by operating activities | 1,301 |
| Purchase of property and equipment | 173 |
| Net cash used in investing activities | -173 |
| Payments under finance lease obligations | 11 |
| Net cash used in financing activities | -11 |
| Net increase in cash | 1,117 |
| Cash and cash equivalents at beginning of period | 3,615 |
| Cash and cash equivalents at end of period | 4,732 |
INTEGRATED BIOPHARMA INC (INBP)
INTEGRATED BIOPHARMA INC (INBP)